Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
By News Desk Published on May 8, 2025, 19:50 IST
Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (YoY) increase. On a like-for-like basis, the revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI).
EBITDA rose 16% YoY to Rs 1,115 crore with an EBITDA margin of 25%. Core EBITDA, excluding R&D and other adjustments, came in at Rs 1,363 crore with a margin of 31%.
The company posted a net profit of Rs 344 crore in Q4FY25, a significant 153% YoY jump. On a like-for-like basis, the net profit rose 162% YoY. Profit before tax (PBT) surged 53% YoY to Rs 487 crore. Segmental performance Generics : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S.
: Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. Biosimilars : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY.
: Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. Research Services (Syngene): Revenue climbed 11% YoY to Rs 1,018 crore. Full-year FY25 highlights
For the full year, Biocon reported: Total revenue : Rs 16,470 crore, up 5% YoY (8% like-for-like)
: Rs 16,470 crore, up 5% YoY (8% like-for-like) EBITDA : Rs 4,374 crore, up 5% YoY
: Rs 4,374 crore, up 5% YoY Net profit: Rs 1,013 crore, down 1% YoY; however, like-for-like net profit increased 30% Dividend and capital plans
The Board recommended a final dividend of Rs 0.50 per share. Additionally, it approved raising up to Rs 4,500 crore through various financial instruments for debt repayment and strategic investments. Strategic developments
Biocon Biologics launched its fifth biosimilar, Yesintek (bUstekinumab), in the U.S. and Germany, and secured a U.S. market entry for Yesafili (bAflibercept). The company also partnered with Civica Inc. to increase access to insulins.
Syngene crossed Rs 1,000 crore in quarterly revenue for the first time and acquired a biologics manufacturing facility in the U.S., expanding its CDMO capabilities.
Biocon has also initiated an evaluation of a potential merger between Biocon Limited and Biocon Biologics. Sustainability
Biocon and Biocon Biologics were both included in the S&P Global Sustainability Yearbook 2025, with Biocon ranked among the top 5% in the Biotechnology sector.
News desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun
Zen Technologies shares are in focus today after introducing its Four-Barrel Rotary Machine Gun, designed for counter-drone and high-intensity combat operations. The weapon features a rapid firing rate of up to 3,500 rounds per minute and an electronically operated firing mechanism, positioning it as a cutting-edge solution in modern warfare. Zen Technologies (@ZenTechnologies) Four-Barrel Rotary Machine Gun Featuring a firing rate of up to 3,500 rounds/min and dependable electronic operation, it stands as the premier weapon for counter-drone operations and intense combat scenarios. — Alpha Defense™🇮🇳 (@alpha_defense) June 10, 2025 The stock opened at ₹2,030.90 and touched an intraday high of ₹2,057.90, before slipping to a low of ₹2,015.00. It remains significantly below its 52-week high of ₹2,627.00 but well above the 52-week low of ₹945.35. As of 11:50 AM, the shares were trading 0.56% higher at Rs 2,025.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
OneSource Specialty Pharma shares jump 3% after USFDA grants VAI classification for its Bangalore facility
By Aman Shukla Published on June 10, 2025, 09:22 IST Shares of OneSource Specialty Pharma Ltd jumped 3% in morning trade on June 10 after the company announced that its flagship facility in Bangalore received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration (USFDA). As of 9:21 AM, the shares were trading 3.61% higter at Rs 2,002.70. The classification follows a routine USFDA inspection conducted from March 20 to March 28, 2025. At the end of the inspection, the agency issued a Form 483 with four observations. The company responded with a comprehensive corrective action plan. After reviewing the response, the USFDA designated the outcome as VAI, indicating that while issues were noted, they were not serious enough to trigger regulatory or enforcement action. The VAI status also confirms that the inspection is now officially closed. The company did not disclose the specific details of the observations, but emphasized that the facility remains integral to its core manufacturing and development operations. A VAI classification is generally seen as a positive regulatory outcome, especially compared to more severe classifications like 'Official Action Indicated' (OAI). Investors reacted favorably to the news, pushing the stock higher. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Markolines bags Rs 16.75 crore work orders from Vadodara Kim Expressway
By Aditya Bhagchandani Published on June 10, 2025, 10:22 IST Shares of Markolines Pavement Technologies Limited may be in focus on Tuesday after the company announced receipt of two work orders worth Rs 16.75 crore (inclusive of GST) from Vadodara Kim Expressway Pvt. Ltd. The contracts are for rain cut repair works at the project site and are to be executed by July 31, 2025. According to the company's regulatory filing dated June 10, 2025, the first work order is valued at Rs 13.81 crore, and the second at Rs 2.94 crore. Both orders are from a domestic entity, and there is no promoter or related party involvement in the awarding of these contracts. The company emphasized that the orders are in the ordinary course of business and fall under the SEBI Listing Obligations and Disclosure Requirements (LODR) norms for material developments. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
